Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction
ConditionErectile Dysfunction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age19-80
SponsorPharmicell Co., Ltd.
About this trial
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Eligibility criteria
Qualifiers
Participants who previously participated in the parent clinical trial and received the cell therapy (Cellgram-ED).
Participants who have provided written informed consent to participate in this safety follow-up study.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
32 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov